Bioinformatics, which is connected to genetics and genomics, uses computer technology to gather, store, analyze, and share biological information and data such as DNA and amino acid sequences or annotations about those sequences.  The main product and service types of bioinformatics are knowledge management tools, data analysis platforms, and services. Knowledge management tools are technologies used by organizations to share information both internally and externally. The various applications include metabolomics, molecular phylogenetics, transcriptomics, proteomics, chemoinformatics, genomics, and others that are used by pharmaceutics, animal studies, agriculture, forensic science, and other end users. The bioinformatics market research report is one of a series of new reports from The Business Research Company that provides bioinformatics market statistics, including bioinformatics industry global market size, regional shares, competitors with a bioinformatics market share, detailed bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the bioinformatics industry. This bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bioinformatics market will grow from $13.02 billion in 2022 to $14.68 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bioinformatics market is expected to grow to $24.46 billion in 2027 at a CAGR of 13.6%. Increasing demand for protein sequencing is driving growth in the bioinformatics market. Protein sequencing refers to the process of determining the sequence of amino acids in all or part of the proteins present in DNA, based on which specific functions, activities, origin, or localization of the protein are determined. Protein sequencing helps analysts to understand the distribution of amino acids along the sequences and the structure of proteins. With bioinformatics methods and databases, the capacity, structure, and developmental history of proteins can be effectively identified. The demand for protein sequencing is expected to grow on account of factors such as advancements in clinical mass spectrometry and analytical techniques, and the significant adoption of target-based drug development by pharmaceutical and biotechnology companies. For instance, in 2021, the total number of protein sequences in UniProtKB, which is a freely accessible database of protein sequence and functional information, increased to approximately 190 million. The lack of interoperability among various available data formats is acting as a restraint on the bioinformatics market. Various data formats come with differences in structures of data. There are numerous protein databases available through various resources, and each database chooses to represent proteins in a different format. Also, different data models such as object data model or relational data model are used while collecting data. Therefore, the problem of interoperability arises when a researcher tries to integrate the results of unique databases present in different data formats. Various data formats available for bioinformatics include Compressed Row Storage (CRS), Sparse Vector, Avro, Parquet and ORC (Optimized Row Compressed). According to a report by Pharmaphorum, an estimated 80% of the researchers’ time is spent on data grooming and only 20% on actual data analysis. This is essentially due to the lack of standardized file types and inconsistent data formatting, which means that every new program results in a new data format. The interoperability issues arising from the use of multiple data formats are affecting the market growth. Companies in the bioinformatics market are increasingly investing in the research and development of nanopore sequencing technology. Nanopore sequencing is a single molecule DNA sequencing technology that eliminates the need for Polymerase Chain Reaction or chemical labeling of the sample. This technology passes ionic current through nanopores (a pore of nanometer size) and when the biological molecules pass through the nanopores or near to it them this technology measures the changes in current which can be used to identify the molecule. Nanopore sequencing technology offers high throughput, low cost, longer reads (Sequence of a section of a unique fragment) to the analyst and helps in the collection of data which is an essential part of bioinformatics. For instance, in 2020, Oxford Nanopore Technologies raised $109.5 million to support the ramp of commercial and manufacturing operations and to further develop its nanopore technology. The bioinformatics market is governed by various regulatory bodies for quality and compliance of bioinformatics platforms. For instance, in India, the Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT), Government of India, regulates the bioinformatics market. BIRAC introduces Technology Readiness Levels (TRLs) as a measure of estimating the maturity of technology while in the evaluation phases until these technologies are complete to be offered commercially. The TRL scale provides 9 technology readiness levels with TRL1 being the stage when the technology is ideated, and TRL9 being the stage when the technology is ready for commercial use. The manufacturers have to get past TRL9 to have their products available commercially and ready to be marketed. These TRL's consist of various levels of compliance and processes that the manufacturers must adhere to. The bioinformatics platform is evaluated for quality, feasibility, data privacy, and protection as per international standards. In September 2020, APIS Assay Technologies Ltd., a UK-based Biotechnology company acquired BeoGenomics for an undisclosed amount. With the addition of Beogenomics’ proven expertise in bioinformatics APIS Assay Technologies Ltd can more effectively capture the exciting opportunities presented in the bioinformatics space. BeoGenomics, a USA-based bioinformatics company that focuses on NGS, SNP chip, and GeneChip genomic data processing and analysis. Major players in the bioinformatics market are Agilent Technologies, Illumina, QIAGEN, Affymetrix, Thermo Fisher Scientific, BGI, Dassault Systems, Eurofins scientific, Bruker Daltonics, Biomax Informatix, DNASTAR, Partek, Geneva Bioinformatics, Perkinelmer Inc., Accelrys, SA Nonlinear Dynamics, Quest Diagnostics, Sophia Genetics, Waters Corporation, Permin Elmer Inc., Applied Biologicals Materials., Life Technologies, PerkinElmer, Waters Corporation, Sophia Genetics, Celera, Tripos, LP, Helicos Biosciences Incorporation, and IBM Life Sciences. North America was the largest region in the bioinformatics market in 2022. Western Europe was the second largest region in the global bioinformatics market. The regions covered in the global bioinformatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The bioinformatics market includes revenues earned by entities by providing solutions which combine computer programming, information engineering, mathematics, and statistics to analyze biological data for drug discovery and preclinical studies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bioinformatics market is segmented - 1) By Products and Serivces: Knowledge Management Tools, Data Analysis Platforms, Services 2) By Application: Metabolomics, Molecular Phylogenetics, Transcriptomics, Proteomics, Chemoinformatics, Genomics, Other Applications 3) By End Users: Pharmaceutics, Animal Study, Agriculture, Forensic Science, Other End Users

The antiemetics and antinauseants refer to drugs that are used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. Antiemetic and antinauseant drugs prevent, control, or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu, or chemotherapy. These drugs reduced the symptoms of nausea or vomiting by blocking signal messages to the part of the brain that controls nausea and vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonists, antihistamines (h1 histamine receptor antagonists), cannabinoids, and benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists, and others. A dopamine antagonist also referred to as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others and is implemented in various sectors such as hospitals, medical centers, clinics, and research institutes. The antiemetics and antinauseants market research report are one of a series of new reports from The Business Research Company that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antiemetics and antinauseants market size will grow from $7.76 billion in 2022 to $8.09 billion in 2023 at a compound annual growth rate (CAGR) of 4.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antiemetics and antinauseants market size is expected to grow to $9.12 billion in 2027 at a CAGR of 3.0%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatments to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by the Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac), and other serotonin 5-HT3 receptor types of antagonists. An increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for the market. Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the market. Despite the presence of a range of drugs, the practitioners prescribe similar drugs to treat patients with different conditions of nausea. The popularity of only a few drugs leads to lower demand for other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kinds of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specifically targeted sites in a controlled manner through Nanomedicine and Nano delivery systems. Nanomedicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drug manufacturers are inclining more toward the use of Nanomedicine or Nano drugs to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is the first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of the Food and Drug Administration Department of Health and Human Services, U.S. part 336, contains conditions that all Antiemetic and Antinauseant drugs are required to fulfil to remain in the market, such as definitions, regulations, and regulations related to the labelling of the antiemetic drug products. Major players in the antiemetics and antinauseants market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Eli Lilly and Company, Merck, Eisai, Bristol-Myers Squibb, and SRS Pharmaceuticals. North America was the largest region in the drugs for antiemetics and antinauseants market in 2022. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market. The regions covered in the global antiemetics and antinauseants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antiemetics and antinauseants market is segmented - 1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types 2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes

The laboratory informatics refer to software products that are used for instrument control, scientific data management, scientific search, network integration, and compliance management to streamline analytical laboratory operations. The laboratory informatics solutions reduce operational costs, accelerate decision-making, improve laboratory processes and others. The main types of laboratory informatics are laboratory information management systems (LIMS), electronic lab notebooks (ELN), chromatography data systems (CDS), electronic data capture (EDC) & clinical data management systems (CDMS), laboratory execution systems (LES), enterprise content management (ECM), scientific data management systems (SDMS). A LIMS (Laboratory Information Management System) is software that helps you to handle samples and data efficiently. Your lab can automate workflows, integrate equipment, and manage samples and associated data with the help of a LIMS. The components of laboratory informatics are services and software which are deployed on-premise, cloud-based, or remotely hosted. The various industries that use laboratory informatics are life sciences industry, chemicals industry, food & beverage and agriculture industry, petrochemical refineries and oil & gas industry, environmental testing laboratories, and other industries. The laboratory informatics market research report is one of a series of new reports from The Business Research Company that provides laboratory informatics market statistics, including laboratory informatics industry global market size, regional shares, competitors with a laboratory informatics market share, detailed laboratory informatics market segments, market trends and opportunities, and any further data you may need to thrive in the laboratory informatics industry. This laboratory informatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global laboratory informatics market size grew from $3.48 billion in 2022 to $3.75 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The laboratory informatics market size is expected to grow to $5.21 billion in 2027 at a CAGR of 8.5%. The increasing need for laboratory automation is expected to propel the growth of the laboratory informatics market during the forecast period. The frequent occurrence of human errors in laboratory operations led laboratory organisations to shift towards automated solutions. For instance, according to a study published by AZoLifeSciences, 30-86% of pre-analytical in laboratories are associated with human error. Laboratory automation is a process which utilises automated laboratory instruments and advanced analytical software to deliver precise, accurate results at a large scale. It provides improved accuracy and reliability of the data by lowering overall costs associated with manual operations. Therefore, the rising demand for laboratory automation is expected to drive the laboratory informatics market during the forecast period. Technological advancements are key trends gaining popularity in the laboratory informatics market. The companies operating in the laboratory informatics market are increasingly investing in the development of new technologically advanced software suites to meet the specific operational demands from laboratory customers across the globe. For instance, in February 2022, Biosero, Inc., a US-based laboratory automation company, launched the Green Button Go® software suite, which includes automated workflows ranging from a single workstation to operations that span multiple labs. This infusion has a variety of applications, such as controlling and scheduling multiple instruments and devices in the lab from a single interface. The technology uses automation by running various algorithms and codes to store and give the results. In January 2022, CliniSys, a US-based company operating in digital innovation and intelligent informatics for laboratories acquired HORIZON Lab Systems, LLC for an undisclosed amount. Through this acquisition, CliniSys aims to strengthen its portfolio in cloud-based lab solutions, for the environmental, public health, toxicology, and agricultural sector. HORIZON Lab Systems, LLC is a US-based healthcare information management company. Major players in the laboratory informatics market are Thermo Fisher Scientific Inc., LabVantage Solutions Inc., LabWare, Abbott Informatics, LabLynx Inc., Waters Corporation, Autoscribe Informatics, and LABWORKS LLC, Cerner Corporation, McKesson Corporation, IDBS, Arxspan LLC, Kinematik, RURO Inc., and Accelerated Technology Laboratories. North America was the largest region in the laboratory informatics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the laboratory informatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the laboratory informatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The laboratory informatics market includes revenues earned by entities by providing software tools and services to streamline laboratory operations such as collecting, analyzing, and sharing data in a laboratory setting to enhance the decision-making process in healthcare-related studies. It also provides the services such as cloud-based services, consulting services, and recurring support services to manage health informatics systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global laboratory informatics market is segmented - 1) By Type: Laboratory Information Management Systems (LIMS), Electronic Lab Notebooks (ELN), Chromatography Data Systems (CDS), Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS), Laboratory Execution Systems (LES), Enterprise Content Management (ECM), Scientific Data Management Systems (SDMS) 2) By Component: Services, Software 3) By Deployment Model: On-premise, Cloud-based, Remotely Hosted 4) By Industry: Life Sciences Industry, Chemicals Industry, Food & Beverage and Agriculture Industry, Petrochemical Refineries and Oil & Gas Industry, Environmental Testing Laboratories, Other Industries

Laboratory automation systems refer to the use of instruments to carry out laboratory tasks with a minimum of human involvement. Clinical laboratories operate more efficiently because of laboratory automation, which helps to standardise tests. The main equipment and software of laboratory automation systems are automated liquid handling, microplate readers, standalone robots, automated storage and retrieval systems, software, informatics, and other equipment. The microplate reader is an instrument that is used to measure biological, chemical or physical reactions of analytes within the wells of the microplate. The various types include modular automation, total lab automation that is used in applications such as drug discovery, clinical diagnostics, genomics solutions, proteomics solutions, and other applications. The end users covered in this market are biotechnology and pharmaceutical industries, research institutes, hospitals, private labs, and academic institutes. The laboratory automation systems market research report is one of a series of new reports from The Business Research Company that provides laboratory automation systems market statistics, including laboratory automation systems industry global market size, regional shares, competitors with a laboratory automation systems market share, detailed laboratory automation systems market segments, market trends and opportunities, and any further data you may need to thrive in the laboratory automation systems industry. This laboratory automation systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global laboratory automation systems market grew from $5.87 billion in 2022 to $6.21 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The laboratory automation systems market is expected to grow from $7.43 billion in 2027 at a CAGR of 4.6%. Increased demand for microbiology testing and standardization of sample-collection devices for microbiology culture has driven the adoption of automated laboratory systems for culture-based laboratory testing in clinical microbiology. Culture-based microbiology laboratory testing by manual methods is being replaced by automated methods with the help of total laboratory automation. For instance, popular systems such as Becton Dickinson’s Kiestra TLA, Copan’s WASPLab, and others enable total laboratory automation (TLA) for culture-based microbiology testing. The potential to affect laboratory efficiency, turnaround time, and the overall quality of culture-based microbiology testing, is driving the automated laboratory systems market growth. The laboratory automation systems market growth is limited due to a severe shortage of skilled and trained healthcare professionals for operating the advanced laboratory equipment which requires specialized skillsets. These skillsets are limited to some hospitals, research organizations, and medical equipment companies in the USA and Europe, this is expected to be a major restraint on the market. 40% of the healthcare industry was facing difficulties in hiring process development staff due to a shortage of talent. According to the American Society for Clinical Pathology (ASCP) survey, average job-vacancy rates exceed 50% in some states. This shortage also led to a rise in competition and salaries for the limited talent pool available, thereby further limiting the market growth. The hospital laboratories are increasingly adopting RFID technology for laboratory automation systems due to its better productivity and product quality reduced costs for technology, error reduction, faster delivery of samples, and reduced human intervention. Radio Frequency Identification (RFID) technology is an automatic system of identification based on wireless communication, consisting of a tag and a reader which can communicate through radiofrequency. RFID technology is similar to bar code technology but is more beneficial as it can perform some additional functions and actions automatically without human intervention than bar code technology. An RFID system is equipped with a transponder, transceiver, and a data processing unit to meet enhanced identification and tracking requirements in hospital laboratories. Laboratory automated systems use RFID tags attached with patient samples for identification and smart cards to store patients’ data under a workstation that monitors the process in the laboratory. For instance, Mayo Clinic, a healthcare company, adopted RFID-enabled laboratory automation systems to minimize errors by 70%, maximize efficiency and patient safety, and reduce specimen turnaround time by 50%. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) is responsible for technologies, devices, medical or surgical equipment, support systems, and laboratory instruments, systems, and equipment. FDA sent a device recall notice to enGen Laboratory Automation System, a medical device manufacturer, for its product-enGen Track System with TCAutomation Software Version 4.2. This recall acts as a product correction notification as a laboratory system with TCA Software V4.2 may potentially cause a delay in reporting of results, aid mechanical problems, and inaccurate patient data. To reduce incidences associated with these devices and let the manufacturer communicate and inform about the instructions on how to monitor and correct the issue if it has occurred to the potentially affected enGen customers, the device recall has been made. In March 2021, SPT Labtech, a UK-based automated instrumentation manufacturer, acquired BioMicroLab for an undisclosed amount. The acquisition would strategically expand product offerings of SPT Labtech in the fields of life sciences sample mangament. BioMicroLab is a US-based robotics automation provider for life sciences laboratories. Major players in the laboratory automation systems market are Tecan Group, Perkinelmer, Thermo Fisher Scientific, Agilent Technologies, Danaher, Qiagen, Roche, Abbott, Siemens, and Eppendorf. North America was the largest region in the laboratory automation systems market in 2022. Western Europe was the second largest region in the global laboratory automation systems market. The regions covered in the global laboratory automation systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the laboratory automation systems market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The laboratory automation systems market consists of sales of clinical laboratory machines, equipment, and instruments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global laboratory automation systems market is segmented - 1) By Equipment & Software: Automated Liquid Handling, Microplate Readers, Standalone Robots, Automated Storage And Retrieval Systems, Software And Informatics, Other Equipment 2) By Application: Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions, Other Applications 3) By End User: Biotechnology And Pharmaceutical Industries, Research Institutes, Hospitals And Private Labs, Academic Institutes 4) By Type: Modular Automation, Total Lab Automation

Chemical compounds are substances that are produced based on the transformation of organic and inorganic raw materials by a chemical process and the formulation of products. Chemicals have characteristics such as flammability, toxicity, acidity, reactivity, and heat of combustion. The main types of chemicals are general chemical products, printing inks, toiletries, soap and cleaning compounds, adhesives, paints and coatings, pesticide and other types of agricultural chemicals, chemical fertilizers, synthetic rubber and fibers, plastic material and resins, ethyl alcohol, and other basic types of organic chemical, and other types of basic inorganic chemical, synthetic dye, and pigment, industrial gas, and petrochemicals. Printing ink is ink used in printing and contains a pigment or pigments of the required color mixed with oil or varnish. The types of intermediate chemicals are methanol, ethylene oxide, and propylene oxide. The end-users involved are pharmaceuticals, agrochemicals, water treatment, construction, paints and dyes, oil and gas, rubber chemicals, surfactants, personal care, and other end-users. The chemicals market research report is one of a series of new reports from The Business Research Company that provides chemicals market statistics, including chemicals industry global market size, regional shares, competitors with a chemicals market share, detailed chemicals market segments, market trends and opportunities, and any further data you may need to thrive in the chemicals industry. This chemicals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global chemicals market grew from $4700.13 billion in 2022 to $5079.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The chemicals market is expected to grow to $6851.59 billion in 2027 at a CAGR of 7.8%. Interest rates were low in most developed countries during this period. This positively impacted the growth of the chemicals market. For instance, in March 2020, the Bank of England, a UK-based central bank, reduced interest rates to 0.1%, the lowest level ever, as a measure of protest against COVID-19. These low-interest rates encouraged borrowing and increased the flow of money for investment. This allowed chemical companies to borrow money for process improvements, thus driving the market during the historic period. Rising costs had a negative impact on the growth of the industrial gas market during the forecast period. This rise in raw material costs resulted in higher manufacturing costs, thus decreasing the investments available for research and development of new products. Additionally, companies invested heavily in marketing their products due to intense competition in the market. Rising trucking, railroad, dry-bulk, and air-freight rates also negatively impacted the market. This rise in operating costs increased the pressure on companies to protect margins while maintaining the quality of their products. Chemical companies are increasingly adopting sustainable and eco-friendly processes to eliminate the negative impact of chemical manufacturing on the environment. Evolution in technology and chemical sciences enables chemical companies to utilize alternative fuels to produce chemical products. They are using naturally available carbon dioxide to produce fuels, industrial products, and other substances. For instance, Akzo Nobel N.V., a chemicals and coatings giant, is planning to make a seven-figure investment in Green Lizard Technologies’ patented process to make surfactants from plants rather than from oils. Major companies in the chemicals market include JXTG Holdings Inc., Sinopec Limited, BASF SE, Procter & Gamble, Unilever plc, L'Oreal SA, Dow Inc., Saudi Basic Industries Corporation (SABIC), Mitsubishi Chemical Holdings Corp, and Guardian Industries, LLC. Asia-Pacific was the largest region in the chemicals market in 2022. North America was the second-largest region in the chemicals market. The regions covered in the chemicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the chemicals market are Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Iran, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, Ukraine, USA, and Vietnam. The chemicals market consists of the sales of petrochemicals, industrial gas, ethyl alcohol, organic chemicals and inorganic chemicals, resins, synthetic rubber, and artificial and synthetic fibers and filaments, pesticides, fertilizers, and other agricultural chemicals. The chemicals industry establishments produce a variety of chemical products by processing raw materials such as air, water, natural gas, oil, metals and minerals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global chemicals market is segmented - 1) By Type: General Chemical Product, Printing Inks, Toiletries, Soap and Cleaning Compounds, Adhesives, Paints and Coatings, Pesticide and Other Agricultural Chemicals, Chemical Fertilizers, Synthetic Rubber and Fibers, Plastic Material and Resins, Ethyl Alcohol and Other Basic Organic Chemical, Other Basic Inorganic Chemical, Synthetic Dye and Pigment, Industrial Gas, Petrochemicals 2) By Type of Intermediate Chemicals: Methanol, Ethylene Oxide, Propylene Oxide 3) By End User: Pharmaceuticals, Agrochemicals, Water Treatment, Construction, Paints and Dyes, Oil & Gas, Rubber Chemicals, Surfactants, Personal Care, Other End-Users Subsegments Covered: Oil-Based Printing Inks, Solvent-Based Printing Inks, Water-Based Printing Inks, Lotions (Including Sunscreens), Hair Preparations, Face Creams, Perfumes, Shaving Preparations, Other Cosmetic Preparations, Soap and Other Detergents, Surface Active Agents, Polish and Other Sanitation Goods, Water-Based Adhesives, Solvent-Based Adhesives, Hot-Melt-Based Adhesives, Reactive & Other Adhesives, Water Borne Coatings, Solvent Based Coatings, Powder Coatings, Other Paints and Coatings, Herbicides, Insecticides, Fungicides, Other Pesticide and Other Agricultural Chemicals, Nitrogen Fertilizer, Phosphate Fertilizer, Potash Fertilizer, Synthetic Fibers, Styrene Butadiene Rubber (SBR), Polybutadiene (BR), Ethylene Propylene (EPDM), Other Synthetic Rubber and Fibers, Polypropylene-Plastic Material and Resins, High-Density Polyethylene, Poly-Vinyl Chloride, Polyethylene Terephthalate, Polyurethane, Low-Density Polyethylene, Polystyrene-Plastic Material and Resins, Other Plastic Material and Resins, Synthetic Sweeteners, Plasticizers, Ethyl Alcohol, Silicone (except Resins), Fatty Acids, Gum and Wood Chemicals Synthetic Dye, Synthetic Pigments, Nitrogen, Oxygen, Carbon Dioxide, Hydrogen, Other Industrial Gas, Ethylene-Petrochemicals, Propylene-Petrochemicals, Benzene-Petrochemicals, Xylene, Styrene-Petrochemicals, Toluene, Cumene, Other Petrochemicals

HIV drug refers to an antiretroviral drug that is frequently used to treat HIV. HIV medications prevent the spread of the human immunodeficiency virus (HIV) or other retroviruses in the body. HIV can cause AIDS if it is not treated (acquired immunodeficiency syndrome). Currently, there is no cure that works well. The main types of HIV drugs are nucleoside reverse transcriptase inhibitors (NRTs), non-nucleoside reverse transcriptase inhibitors (NNRT’s), protease inhibitors, integrate inhibitors, fusion inhibitors, chemokine receptor inhibitors, and others. Nucleoside reverse transcriptase inhibitors (NRTIs) are structural nucleoside analogs of DNA nucleotides that inhibit HIV-1 RT and viral replication by preventing reverse transcription of the HIV genome. The drugs are administered through oral and parenteral methods that are used by hospital pharmacies, retail pharmacies, online pharmacies, and others. The HIV drugs market research report is one of a series of new reports from The Business Research Company that provides HIV drugs market statistics, including HIV drugs industry global market size, regional shares, competitors with an HIV drugs market share, detailed HIV drugs market segments, market trends and opportunities, and any further data you may need to thrive in the HIV drugs industry. This HIV drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global hiv drugs market grew from $33.39 billion in 2022 to $35 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hiv drugs market is expected to grow from $42.65 billion in 2027 at a CAGR of 5.1%. The novel coronavirus outbreak has augmented the growth of the global HIV drug market. HIV drugs are repurposed to treat Covid 19 infections. Currently, several countries are evaluating and using antiretroviral drugs (For instance, lopinavir boosted with ritonavir (LPV/r)), for treating coronavirus infection. Increasing awareness among people regarding the diagnosis and treatment of HIV disease acts as an important driver for the growth of the HIV drug market. HIV/AIDS is one of the most chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease. According to WHO, 26 million people were diagnosed with HIV/AIDS in 2020, whereas, 32.7 million people died of AIDS-related illness at the end of 2019. The federal government agencies and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care. Side Effects of HIV Drugs have always been a major challenge in antiretroviral therapy. Antiretroviral drugs are used to treat HIV and AIDS as these drugs help lower viral load, control the growth of the virus, boost the ability to fight infections, prevent HIV transmission to others and help stop or slow down symptoms. These drugs come with both short-term side effects (diarrhoea, difficulty in sleeping, dizziness, fatigue, headache, muscle pain) and long-term side effects (depression, diabetes, heart disease, insomnia). There are several side effects associated with the therapy, thus impacting the growth of the market. The antiretroviral drugs market is increasingly implementing multi-class combination products for the treatment of antiretroviral therapy. Combination drugs combine multiple medications into one drug form. Examples of multiclass combination drugs or single-tablet regimens (STRs) include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). Based on drug class, drugs are segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Others. Multi-class Combination Products are the rising burden of HIV and new drug approval. According to WHO, In 2021, 1.5 million [1.1-2.0 million] people contracted HIV, and 650 000 [510 000-860 000] people died from HIV-related causes. Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs to maintain their competitive advantage and penetrate new regional markets. Major players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson&Johnson), F. HOFFMANN-LA ROCHE Ltd., Boehringer Ingelheim (C.H. Boehringer Sohn AG & Ko. KG), AbbVie, Inc., GlaxoSmithKline PLC., Mylan Pharmaceuticals, Pfizer, TEVA PHARMACEUTICAL INDUSTRIES Ltd., Hetero Drugs, Daiichi Sankyo, Emcure, AstraZeneca, CIPLA, Alexion Pharmaceuticals, Shionogi, Theratechnologies, and Abbott Laboratories Inc. North America was the largest region in the HIV drugs market in 2022. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the global HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the HIV drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The HIV drug market consists of sales of Tivicay, Triumeq, Truvada, and Vemlidy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global HIV drugs market is segmented - 1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Other Types 2) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Applications 3) By Administration: Oral, Parenteral

Interventional oncology devices are used in the diagnosis and treatment of cancer using minimally invasive techniques and advanced imaging technology. The main products of interventional oncology devices are embolization devices, ablation devices, and support devices. The embolization devices are intended for the embolization of the blood vessels of a variety of tumors. The interventional oncology devices are used to perform procedures such as thermal tumour ablation, non-thermal tumour ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE), or bland embolization, that are used to treat cancer types such as liver cancer, kidney cancer, lung cancer, bone cancer, and others. The interventional oncology devices market research report is one of a series of new reports from The Business Research Company that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional oncology devices market size will grow from $2.21 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional oncology devices market size is expected to grow from $3.03 billion in 2027 at a CAGR of 6.5%. The availability of private and government funding drove the interventional oncology devices market. In the field of cancer, funding from the government and private has increased, especially for the devices used in treatments as it promotes early detection and better survival rates. The American Cancer Society, the largest non-government, not-for-profit cancer research funder, has awarded 630 projects with a grant amount of $384,262,652 in 2021. BioProtect Ltd., an Israeli company that develops novel bioabsorbable polymer spacer balloons, received a funding of $13 million of its Series D equity financing from a leading global syndicate of venture investors that finances the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. Endosight, the first augmented-reality-guided ablative system, has received 20% of its funding from private organizations. The funding from government and private organizations helps in the development of new technologies and devices, thereby driving the interventional oncology devices market. Rising product recalls are likely to hinder the demand for interventional oncology devices. The number of interventional oncology product recalls has risen. For instance, in June 2020, the IceFORCE 2.1 CX Prostate Cryoablation Kit Visual ICE System of the Boston Scientific Corporation was recalled as the needle surface had deteriorated. In March 2020, Medtronic recalled the Pipeline Flex embolization system with Shield technology due to a fracture in the distal portion. These product recalls put financial strain on businesses and also hampers the demand, thus hindering the market. Companies are focusing on deploying robotics technology in interventional oncology devices, for higher efficiency. The robotic system integrates image-based planning and navigation with the installation of different instruments to the desired body part with better accuracy and efficiency. For instance, in March 2022, the U.S. Food and Drug Administration approved Quantum Surgical’s Epione interventional oncology robotics platform. In July 2020, Terumo Corporation, a Japanese medical device company, acquired Quirem Medical for $45 million. Through this acquisition, Terumo intends to launch the Holmium platform globally as a part of the ongoing expansion of its interventional oncology (IO) portfolio. It further strengthens the brand and extends manufacturing and clinical development activities. Quirem Medical is a Netherlands-based medical device company that develops and markets Holmium-166-based radioactive microspheres for Selective Internal Radiation Therapy (SIRT). Major players in the interventional oncology devices market are Boston Scientific Corporation, Medtronic PLC., Terumo Corporation, Merit Medical Systems Inc., Philips Volcano, AngioDynamics Inc., GE Healthcare, Siemens Healthineers, Sirtex Medical, and Cook Medical Incorporated. North America was the largest region in the interventional oncology devices market in 2022. Asia-Pacific was the second largest region in the global interventional oncology devices market report. The regions covered in the global interventional oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional oncology devices market is segmented - 1) By Product: Embolization Devices, Ablation Devices, Support Devices 2) By Procedure: Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT), Transcatheter Arterial Embolization (TAE) or Bland Embolization 3) By Cancer Type: Liver Cancer, Kidney Cancer, Lung Cancer, Bone Cancer, Other Cancer Types

Intravenous infusion pumps are medical devices used for controlled delivery of drugs into the patient's body. The intravenous infusion pumps market covered in this report is segmented by product into the volumetric, syringe, enteral, ambulatory, IV disposables, and others. A syringe is a reciprocating pump used to deliver drugs and consists of a plunger. It is also segmented by application into chemotherapy, diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, haematology, others, and by end-user into hospitals, ambulatory surgical centers, cancer treatment centers, specialty clinics, and others. The intravenous infusion pumps market research report is one of a series of new reports from The Business Research Company that provides intravenous infusion pumps market statistics, including intravenous infusion pumps industry global market size, regional shares, competitors with a intravenous infusion pumps market share, detailed intravenous infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous infusion pumps industry. This intravenous infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global intravenous infusion pumps market grew from $5.32 billion in 2022 to $5.68 billion in 2023 at a compound annual growth rate (CAGR) of 6.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intravenous infusion pumps market is expected to grow from $7.6 billion in 2027 at a CAGR of 7.5%. The rise in the prevalence of people with chronic pain, cancer, and diabetes is a significant driver of the demand for intravenous infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, which can be attributed to an aging population and shifts in social behavior that lead to a gradual increase of these widespread and expensive long-term medical issues. Infusion pumps are used to transfer regulated doses of nutrients or drugs into a patient's body, such as chemotherapy medicines, pain relievers, antibiotics, insulin, or other hormones. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the intravenous infusion pumps market. The high cost of intravenous infusion pumps is a key factor hampering the growth of the intravenous infusion pumps market. The cost of medication therapies is expected to double when the intravenous infusion pumps in hospitals and pharmacies are networked, as they are pre-programmed with set limits to avoid intoxication or overdoses. For example, the cost of the syringe pump ranges from $2,380 to $5,982. Besides, the pump-hardware support contracts vary between $150 to $250 per pump. Therefore, the high cost of intravenous infusion pumps, which increases the cost of drug therapies, is expected to hinder the market growth for intravenous infusion pumps. The growing technological improvement is a major trend gaining popularity in the intravenous infusion pumps market. Technological advances in infusion pumps have changed medical care in hospitals and allowed patients to inject fluids on an outpatient basis or in a home setting, allowing them to seek treatment while living their daily lives, through the use of smart intravenous infusion pumps. These smart intravenous infusion pumps help prevent medication errors and reduce patient harm. Some of the major companies investing in smart intravenous pumps include Fresenius Kabi, Q-Core Medical, Becton Dickinson, Micrel Medical Devices, and Baxter International. In another instance, vTitan, a Chennai-based healthcare company, announced the launch of the next generation of Syringe Infusion Pumps, which are used for critical care in hospitals and homes for reliable and safe infusion of drugs. In March 2022, Fresenius Kabi, a Germany-based pharmaceuticals company, acquired Ivenix for $240 million in upfront payments and milestone payments. The acquisition would help the company to improve its offerings and help it better serve the customer’s needs. Ivenix is a US-based manufacturer of infusion pumps. Major players in the intravenous infusion pumps market are B. Braun Melsungen AG, Baxter International, Medtronic, Fresenius Kabi, Smiths Medical Inc., Becton Dickinson and Company, Terumo Corporation, F. Hoffmann-La Roche Ltd., ICU Medical Inc., and IRadimed Corporation. North America was the largest region in the intravenous infusion pumps market in 2022. Western Europe was the second-largest region in the global intravenous infusion pumps market. The regions covered in the global intravenous infusion pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the intravenous infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The intravenous infusion pumps market consists of sales of volumetric infusion pumps, syringe infusion pumps, and patient controlled analgesia infusion pumps. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global intravenous infusion pumps market is segmented - 1) By Product: Volumetric, Syringe, Enteral, Ambulatory, IV Disposables, Other Products 2) By End-User: Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Specialty Clinics, Other End Users 3) By Application: Chemotherapy, Diabetes, Gastroenterology, Analgesia/Pain Management, Pediatrics/Neonatology, Haematology, Other Applications